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Abstract
Osteosarcoma management continues to lack the appropriate prognostic tools to assign 
personalised treatment. This leaves non-responders to standard care vulnerable to recurring 
disease and pulmonary metastases. Developing 3D in vitro disease models to serve as a test bed 
for personalised treatment is a promising approach to address this issue. This study describes 
the generation of 3D osteosarcoma models termed “tumouroids”, which are geometrically 
compartmentalised to reproduce the bone cancer mass and its surrounding. Although the tumour 
microenvironment impacts osteosarcoma in many ways, this model was focused on 
interrogating the influence of a biomimetic matrix on tumour cell behaviour. The 3D matrix 
was supplemented with the bone-marrow proteins laminin, fibronectin and NuOss® bone 
granules. This led to increased invasion of osteosarcoma cell aggregates from within the bone-
like matrix into the surrounding acellular bone-marrow-like ECM. The presence of bone 
granules also yielded an atypical molecular profile of osteosarcoma cells, suggesting malignant 
metabolic reprogramming. Changes include decreased MMP-9 (p<0.05) and increased PTEN 
(p<0.05), MCP-1 (p<0.01) and MCT-4 (p<0.05) gene expression. This complex 3D biomimetic 
composition also changed cellular responses to doxorubicin, a common chemotherapeutic agent 
used to treat osteosarcoma, and reproduced key issues of in vivo treatment like drug penetrance 
and doxorubicin-induced bone toxicity. This work highlights the impact of a biomimetic matrix 
in 3D osteosarcoma models for both basic and translational research.
Keywords: 3D model; tumour engineering; osteosarcoma niche; biomimetic; doxorubicin
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1. Introduction
Many cancer patients will obtain little benefit from existing anti-cancer treatments. This is 
particularly true for patients with rare and highly heterogeneous cancers, such as osteosarcoma. 
Osteosarcoma is the most common solid tumour of bones occurring predominantly within the 
metaphyseal medullary cavity of long bones, with high-grade intramedullary osteoblastic 
osteosarcoma the most commonly diagnosed subtype [1]. There is a growing body of evidence 
to suggest that mesenchymal stem cells and their osteoblastic lineage are the cells-of-origin 
resulting in this cancer [2].  Therapeutic efficacy is defined by the Huvos grading system of 
tumour necrosis following chemotherapy and surgical excision, where good responders are 
termed those above the 90% threshold and poor responders those below. However, this 
prognostic system offers no insight on how to manage poor responders. As such, there is an 
urgent need for an osteosarcoma personalised-medicine modality. Whilst basic research 
advances our understanding of disease mechanisms and informs on potential drugable 
signalling nodes, it stops short of informing clinicians about treatment alternatives. 
There is a growing appreciation of the importance of the microenvironment and niche to the 
properties of cancer cells. Like their healthy counterparts, cancer cells exist in a dynamic 3D 
environment mediated by cell-to-cell and cell-to-extracellular matrix (ECM) interactions. Cells 
types within the microenvironment include osteoblasts, osteoclasts, pericytes and (other 
vascular cells) and cells of the haematopoietic lineage [2].The physical niche includes the bone, 
both trabecular and cortical, and the bone marrow. These physical environments confer 
different matrix compositions, matrix architecture, oxygen levels and stiffness. Bone is a highly 
vascular tissue, with a hard, mineralized matrix, mainly composed of collagen and 
hydroxyapatite conferring a young’s modulus of 15.2 GPa [3]. In comparison, bone marrow 
and marrow adipose tissue are composed of collagen, fibronectin, laminin, proteoglycans and 
hyaluronan, and a number of minor components [4]. The young’s modulus of bone marrow 
varies between 0.25-15.7 kPa [5] and is thus much less stiff than bone.  Appreciation of the 
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difference in characteristics of the bone and bone marrow is essential when aiming to replicate 
in vivo biology with an in vitro model of the disease. Indeed, bone density [6, 7], platelet-
assisted intravasation [8-10], hypoxia [11, 12] and matrix composition [13, 14], are all 
mediators of osteosarcoma development. The research presented herein focuses on the role of 
the matrix composition in the osteosarcoma niche on cancer cell behaviour.
Through the adoption of established tissue engineering tools, a new generation of 3D in vitro 
cancer models can be created via tumour engineering. Herein we report the development of 
‘tumouroids’ as a novel 3D in vitro model of osteosarcoma. The aim of this study is to create a 
customisable system that would allow the interrogation of the influence of the ECM on 
osteosarcoma drug sensitivity. Specifically, it aims to understand how non-cellular components 
of the tumour mass and matrix, namely ECM proteins, change invasion of cancer and response 
to a therapeutic insult.  The ‘tumouroids’ are based on the matrix protein collagen type I and 
have a geometrically modular 3D structure. This compartmentalisation allows the composition 
of each module to be varied in order to best represent the cancer mass and the organic and 
inorganic features of its surrounding stroma. Due to the transparency of these cultures it is 
possible to track the migration/invasion of cancer cells into the surrounding ECM as well as 
any changes in cancer mass morphology. The modulation of the matrix composition of 
individual tumouroid compartments had an impact on the morphological and molecular profile 
of cancer cells, which was also reflected in the drug-response to doxorubicin.  
2. Materials and Methods
2.1 Cell culture
The MG-63 (ATCC® CRL-1427™) and the 143B (ATCC® CRL-8303™) human bone 
osteosarcoma cell lines were purchased from ATCC. MG-63 and 143B cells were cultured in 
high-glucose Dulbecco’s Modified Eagle Medium (DMEM) (Thermo Fisher Scientific, Paisley, 
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UK) supplemented with 10% fetal bovine serum (FBS) (Gibco, Loughborough, UK), 1% 
antibiotic-antimyotic solution 100x (Thermo Fisher Scientific, Paisley, UK) and 1% sodium 
pyruvate 100 mM (Thermo Fisher Scientific, Paisley, UK). Cells were maintained in 37oC, 5% 
CO2/air and 95% humidity. Cells were passaged using TryPLE™ Express (Thermo Fisher 
Scientific, Paisley, UK) and then either re-plated with a seeding density of 4x104 cells/cm2 or 
used directly as cell suspension for 3D tumouroid cultures.  
2.2 Fabrication of basic 3D tumouroid cultures
3D tumouroid cultures were generated using a customised protocol of the RAFT™ 3D cell 
culture system (Lonza, Slough, UK) following the manufacturer’s instructions. All reagents and 
workflow solutions were kept on ice unless otherwise stated.  Separate solutions for the cellular 
artificial cancer mass (ACM) and the surrounding acellular ECM were prepared consecutively. 
Firstly, the cellular solution; rat-tail collagen type I 2.1 mg/ml in 0.6% acetic acid (First Link, 
Wolverhampton, UK) was mixed with 10x Minimal Essential Medium (Thermo Fisher 
Scientific, Paisley, UK) and neutralised to a pH ~7 using a 10M NaOH and HEPES solution. A 
cell suspension was then added corresponding to 50,000 cells/gel (20.8x104 cells/ml). The 
collagen-MEM-cell solution (8:1:1 ratio) was then cast in 96-well plates (240 μl/well) and 
placed at 37oC for 15 minutes to allow gelation. Subsequently, RAFT™ absorbers (016-1R33) 
were placed on the hydrogels for 15 minutes to remove excess fluid and increase collagen 
density. 200 μl complete media were added over each gel and the 96-well plate was kept briefly 
at 37oC, 5% CO2/air, 95% humidity until the next steps. The acellular ECM solution; collagen 
was mixed with 10x MEM and neutralised as before, then supplemented with 50 μg/ml laminin 
(Corning, Amsterdam, Netherlands). The collagen-MEM-laminin solution was cast in 24-well 
plates (final volume 1.3 ml) and before the solution polymerised, the ACM was transferred 
from the 96-well plate into the centre of the 24-well plate solution using sterile tweezers. Nested 
hydrogels were set at 37oC for 15 minutes and then compressed using RAFT™ absorbers (016-
1R32) for 15 minutes. This formed the final basic tumouroids (Fig.2.A.). 
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2.3 Fabrication of complex 3D tumouroid cultures
Complex 3D tumouroid cultures were prepared using similar methodology as basic, with 
supplementation of matrix components in the ACM and surrounding ECM. NuOss® cancellous 
bone granules (0.25-1mm; Collagen Matrix Inc., Oakland, NJ USA) were grounded under 
sterile conditions to a particle size <63 μm in diameter (Ø) using a ceramic pestle and a 
stainless-steel sieve (510-4901, VWR International Ltd, Lutterworth, UK). As with basic 
tumouroids, a collagen-MEM-cellular solution was prepared to which 5 mg/ml <63 μm Ø 
NuOss® granules were added, mixed and subsequently cast inside 96-well plates. The ACM 
hydrogels were set at 37oC for 15 minutes and then compressed using RAFT™ absorbers (016-
1R33) for 5 minutes. The acellular collagen solution was supplemented with 25 μg/ml laminin 
and 25 μg/ml fibronectin (Sigma Aldrich) and cast in 24-well plates (final volume 1.3 ml). 
Before gelation, the ACM was transferred from the 96-well plate into the centre of the 24-well 
plate solution using sterile tweezers. The nested hydrogels were set at 37oC for 15 minutes and 
then compressed with RAFT™ absorbers (016-1R32) for 10 minutes. This formed the final 
complex tumouroids (Fig.3.A.). All tumouroids were cultured at 37oC, 5% CO2/air, 95% 
humidity in 1ml/well DMEM and had 50% media change every 48h.   
2.4 Cell proliferation
143B and MG63 basic tumouroids were prepared in triplicates and harvested on Days 0, 3, 5 
and 7 to assess proliferation in 3D. 7 days is the standard duration of tumouroid culture in this 
work unless otherwise stated. Double-strand DNA (dsDNA) quantification was carried out 
using the Qubit® dsDNA High Sensitivity Assay Kit (Thermo Fisher Scientific) following 
manufacturer’s instructions. Briefly, tumouroids were lysed in RLT buffer (Qiagen) plus 10 
μl/ml β-mercaptoethanol (Sigma Aldrich) to avoid interference of phenol-red in TRI Reagent® 
with the fluorochrome reagent in the Qubit® kit [15]. The lysate was diluted 1/10 in nuclease-
free water (Sigma Aldrich). Readings were obtained using the Qubit™ 3.0 Fluorometer and 
were calculated as total dsDNA [ng/μl] per tumouroid. Growth rates were deduced using the 
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curves of best fit (Fig.2.H.). Cell proliferation rates of 2D monolayers was also performed using 
PrestoBlue® Cell Viability Reagent (Thermo Fisher Scientific). A standard curve was deduced 
on Day 0 which was then used to monitor the proliferation of 50,000 cells on days 1, 2 and 4. 
Growth rates were deduced using the curves of best fit (Fig.2.I.).  
2.5 Immunofluorescence
Tumouroids were fixed using 10% neutral buffered formalin solution for 30 minutes at room 
temperature and then washed with PBS (3 x 1 ml/well). Then tumouroids were incubated in 
500 μl 4 μg/ml Phalloidin/PBS solution (P5282, Sigma Aldrich, Dorset, UK) for 45 minutes at 
room temperature in the dark. The tumouroids were then washed with PBS 1 ml/well and 
incubated in 500 μl 5 μg/ml DAPI/PBS solution (D9542, Sigma Aldrich, Dorset, UK) for 15 
minutes at room temperature in the dark. Subsequently, the tumouroids were washed and kept 
in PBS 1 ml/well until imaged using an Apotome.2 (Carl Zeiss, Oberkochen, Germany). Z-
stacks were obtained at 10 μm intervals.
2.6 Characterisation of cell movement in 3D tumouroids       
3D tumouroids were intentionally designed to have an acellular ECM compartment surrounding 
the cellular ACM in order to observe cell migration in response to matrix changes and drug 
treatment. Two distinct patterns of collective cell migration were recorded either cell sheets or 
invasive spheroid bodies (Fig.2.D.). Cell sheets were defined by a disorganised accumulation 
of cells that gradually extended into the surrounding ECM (Fig.2.C.). To deduce a qualitative 
invasion profile of 143B and MG63 tumouroids, the following parameters were monitored at 8 
fixed locations on tumouroid circumference (Fig.2.B.): the maximum distance of cell sheets 
from the ACM margin, the maximum surface area of invasive spheroid bodies and the total 
number of invasive spheroid bodies per tumouroid. Experimental repeats per condition n>2 and 
technical repeats per experiment n>4.
2.7 Gene-expression analysis
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Gene expression analysis was performed in accordance with the MIQE guidelines [16]. Total 
RNA was isolated from day 7 tumouroids; the control condition was tumouroids in a collagen-
only ECM and two test conditions were (1) basic tumouroids in a collagen-laminin [50 μg/ml] 
ECM and (2) complex tumouroids with added NuOss® [5 mg/ml <63 μm Ø] in the ACM 
surrounded by a collagen-laminin [25 μg/ml]-fibronectin [25 μg/ml] ECM. TRI Reagent® 
(Sigma Aldrich, Dorset, UK) was used, following the manufacturer’s instructions for 
phenol/chloroform phase separation. RNA was quantified using a NanoDrop 
spectrophotometer measuring at 260/280 nm and 1000 ng RNA/sample were reverse 
transcribed using the High Capacity cDNA Reverse Transcriptase Kit (Thermo Fisher 
Scientific, Paisley, UK) with the program: 25°C 10 min, 37°C 120 min, 85°C 5 min, 4°C. 
Transcribed cDNA was assessed via the CFX96 Touch™ Real-Time PCR Detection System 
(40 cycles) using the iTaq Universal SYBR Green Supermix (Bio-Rad, Hertfordshire, UK). 
Primers were designed using Primer3Plus and NCBI Primer-BLAST, specific to the Homo 
sapien genes: PTEN, MMP-9, MCP-1 (also known as CCL2), VEGF-A and MCT-4. Relative 
gene expression was calculated using the 2-ΔCT method using the reference gene GAPDH, 
which was ranked first as a reference gene in regard to its stability of expression in sarcomas 
[17].
Table 1. RT-qPCR primers
Gene Forward Primer (5’ to 3’) Reverse Primer (5’ to 3’)   size
PTEN AATGTTCAGTGGCGGAACTTGC CACACACAGGTAACGGCTGAGG 140
MMP9 TTCTGCCCGGACCAAGGATA ACATAGGGTACATGAGCGCC 109
MCP1 TCAAACTGAAGCTCGCACTCT CATTGATTGCATCTGGCTGAG 119
VEGFA GTGAATGCAGACCAAAGAAAGA CTCCAGGGCATTAGACAGCA 148
MCT4 CCACATCAAAGGGATCTTCTGC CCATCCTCCATCCAGGGTTTT 100
2.8 Doxorubicin-response assay
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Basic and complex 3D tumouroids were cultured for 7 days to allow invasion into surrounding 
ECM and were then exposed for 24h to Doxorubicin hydrochloride at concentrations 0.1 μM, 
1 μM and 10 μM (n=12 per condition), which corresponds to plasma Cmax 50-5000 ng/ml. To 
quantify cell death, tumouroids were processed with the Qubit® dsDNA High Sensitivity Assay 
Kit, as previously described. To assess metabolic changes, tumouroids were also treated with 
PrestoBlue® Cell Viability Reagent (Thermo Fisher Scientific) following manufacturer’s 
instructions. This Resazurin-based assay induces changes in Absorbance at 600 nm which were 
recorded using a Tecan Infinite® 200 PRO plate reader. To observe drug uptake in tumouroids, 
fluorescence imaging was performed using the Apotome.2 as doxorubicin hydrochloride emits 
at λem 595 nm.
2.9 Statistical Analysis
Data were collected from biological repeats n>2 and technical repeats per condition n≥4. The 
results are presented as mean ± SEM. Kolmogorov-Smirnov test was performed to compare 
cumulative distributions and determine whether subsequent analysis required parametric or 
non-parametric testing. Unpaired Student’s t test was used to compare two parametric sample 
populations. For more than two populations, a one-way ANOVA and post hoc Tukey's multiple 
comparisons test was performed and for the drug-response data analysis a two-way ANOVA 
with post hoc Sidak’s multiple comparisons test was performed using GraphPad Prism 6. 
(Graph-Pad, San Diego, CA). The significance level of α = 0.05 was accepted. (p<0.05 *, <0.01 
**, <0.001 ***).
3. Results
3.1 Highly metastatic 143B cells proliferate faster in basic tumouroids
High-metastatic 143B and low-metastatic MG63 human osteosarcoma cell lines [18] were used 
to form basic 3D tumouroid cultures. They were defined as ‘basic’ due to their baseline ECM 
composition of only collagen type I and laminin (Fig.2.A.). Viability, proliferation rate and 
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morphological behaviour of cells in 3D was assessed following 7-14 days of culture. 
Consecutive dsDNA quantification of tumouroids revealed that both cell lines were viable and 
proliferated exponentially over the 7-day culturing period. A 3-fold higher proliferation rate of 
143B compared to MG63 tumouroids was recorded by day 7 (Fig.2.H.). This is in line with the 
2-fold higher proliferation rate of 143B cells compared to MG63 in 2D monolayers (Fig.2.I.).  
3.2 Highly metastatic 143B cells invade as larger spheroid bodies into acellular ECM
3D cell behaviour was monitored daily using brightfield microscopy and fluorescence 
microscopy measurements. After 7 days of culture it was observed that both cell types in basic 
tumouroids had migrated from their original seeding location, the ACM, outward into their 
surrounding acellular ECM (Fig.2.B&2.E.). This was apportioned to both cell proliferation and 
collective cell migration. To confirm that this observation was not a displacement effect of the 
overgrowing cancer cells, untransformed mesenchymal stem cells (MSCs) were used to 
populate the ACM and were tracked using the CM-Dil cell-tracker dye (Suppl.Fig.1.A-B). 
MSCs were used for this approach because the cell-tracker dye would have been undetected 
after 24h in the two OS cell lines due to their high proliferation rate, which is not sufficient time 
to observe invasion in the surrounding ECM. Following the standard 7 day incubation, MSCs 
were imaged in the acellular ECM compartment with both faded and intact cell-tracker dye 
(Suppl.Fig.1.C-D) thus confirming both migration and proliferation taking place in our 3D 
culturing system. Two types of collective cell migration were recorded; cell sheets (Fig.2.B-C.) 
and spheroid bodies (Fig.2.B&2.D.). The former was defined as overlapping cell monolayers 
with no apparent organisational pattern (Fig.2.C.) whereas the latter was defined as 3D cellular 
bodies with a spheroid organisation. Invasive spheroid bodies grew either attached to the 
circumference of the ACM or detached and migrated into the surrounding ECM (Fig.2.D.). Due 
to the 2 types of aggregation and invasion patterns, and the fact that spheroid bodies were not 
perfect spheres, a measurement of their surface area was selected to define growth. In this 3D 
model, the formation of invasive spheroid bodies was associated with an aggressive cancer 
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phenotype and the high-metastatic 143B cells, as these developed invasive spheroid bodies of 
359.6 ± 75 mm² surface area. These were significantly larger than in the low-metastatic MG63 
tumouroids which generated invasive spheroid bodies of 133.3 ± 9.7 mm² (Fig.2.G.).
3.3 Addition of matrix components results in enhanced cancer invasion
Complex osteosarcoma tumouroids were so termed due to the addition of matrix components 
relating to the osteosarcoma niche i.e. the intramedullary cavity, forming a complex ECM. 
Finely ground <63 μm Ø cancellous bone granules (NuOss®) were added to the ACM and 
fibronectin was added to the surrounding ECM compartment of tumouroids (Fig. 3.A.). This 
triggered both morphological (Fig.3.B.) and transcriptional changes (Fig.3.G.) in osteosarcoma 
cells following 7 days of incubation. The addition of fibronectin in the acellular ECM, in the 
absence of NuOss®, had no significant effect on either the distance or surface area of invading 
cell bodies (Suppl.Fig.2.A-E.). 143B complex tumouroids produced cell sheets that migrated 
1180 ± 117.4 µm from the ACM and 3.7 ± 0.5 invasive bodies per tumouroid, which was 
significantly greater than their basic counterparts (Fig.3.C.). MG63 complex tumouroids also 
showed a trend for increased stromal invasion as they developed cell sheets 800 ± 64.2 µm far 
from the ACM, however no other parameters showed significant change (Fig.3.D.).
3.4 Increased matrix complexity shifts osteosarcoma gene expression towards metabolic 
reprogramming. 
To further investigate the changes associated with increasing matrix complexity, the expression 
of selected genes that govern processes linked to osteosarcoma aggression [18] were assessed 
via real-time quantitative PCR (RT-qPCR) and correlated to morphological observations. 
Initially, the change in transcript levels of certain genes in response to culturing 143B and 
MG63 cells in 3D collagen instead of 2D monolayers was assessed. Indeed the difference was 
striking as the expression of the gelatinase enzyme matrix metalloproteinase-9 (MMP9) 
increased by 37-fold (p<0.01), vascular endothelial growth factor (VEGF) increased by 4.9-fold 
(p<0.0001) and phosphatase and tensin homolog (PTEN) decreased by 0.5-fold (p<0.001) in 
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the highly metastatic 143B 3D cultures compared to monolayers (Fig.3.H.). Culturing MG63 
in 3D cultures increased MMP9 by 2.4-fold (p=0.05), PTEN by 1.6-fold (p<0.001) and 
decreased VEGF by 0.57-fold (p<0.0001) (Fig.3.I.). Comparing the transcript levels of cells 
from the two different tumouroid compositions revealed greater changes for 143B tumouroids 
(Fig. 3.J.). Indeed, a 28-fold (p<0.05) decrease in the MMP-9 expression was measured in 
complex tumouroids. Furthermore, a 5-fold (p<0.01) increase in expression of monocyte 
chemoattractant protein-1 (MCP-1) and a 1.2-fold (p<0.05) increase of PTEN expression, 
which has an inverse relation to MMP-9, was also apparent when comparing complex to basic 
tumouroids. Although VEGF expression displayed no significant difference between complex 
and basic 143B tumouroids, there was a significant 1.8-fold (p<0.05) increase in complex MG-
63 tumouroids compared to basic (Fig.3.K.). Both 143B and MG-63 complex tumouroids 
displayed a significant increase in monocarboxylate transporter 4 (MCT-4) expression, by 1.5-
fold (p<0.05) and 1.4-fold (p<0.05), respectively.
3.5 Increasing matrix complexity alters drug response of osteosarcoma cells in 3D
Having confirmed that a complex environment, which replicates aspects of the bone 
intramedullary cavity, causes a shift towards an aggressive osteosarcoma phenotype in both 
tested cell lines, the effect of the commonly used anthracycline drug doxorubicin on 3D basic 
and complex tumouroids was tested. Doxorubicin is an antibiotic derived from Streptomyces 
peucetius [19], which has a mechanism of action involving DNA intercalation, blockage of 
DNA biosynthesis by stabilising the topoisomerase II complex thus preventing DNA replication 
[20] and increase of cytotoxicity by free-radical production [19]. Initially, to understand how 
the osteosarcoma cell lines behaved when exposed to doxorubicin, confluent 2D cultures of 
143B and MG63 cells were exposed to 5 increasing drug concentrations (0.1-10 μM) for 24 
hours (Fig.4.A-C.). Quantification of dsDNA indicated that there was significantly (p < 0.0001) 
more cell death in 143B than MG63 monolayers with respect to untreated cells (Fig.4.B.). As 
doxorubicin intercalates in the DNA replication fork of dividing cells, 143B monolayer cultures 
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may be more vulnerable to its effect as they replicate 3-times faster than MG-63 (Fig.4.A.). 
Similarly, the PrestoBlue assay revealed a greater degree of metabolic change in 143B cells 
compared to MG63 for most tested concentrations of doxorubicin (Fig.4.C.). 
The next step was to test the hypothesis that complex tumouroids, which replicated the tumour 
microenvironment, would respond differently to doxorubicin and potentially more like that 
observed clinically. Cells in basic and complex ECM were cultured for 7 days and subsequently 
treated with 0.1, 1 and 10 μM doxorubicin hydrochloride for 24 hours (Fig.4.D-G.). Comparing 
the rate of cell death with respect to untreated tumouroids revealed that, although not 
statistically significant, 143B tumouroids in complex ECM were more resistant to drug 
treatment at concentrations 0.1 and 1 μM. Treatment with 10 μM doxorubicin lead to more cell 
death in complex 143B tumouroids (Fig.4.D). As anticipated from the qPCR (Fig.3.G.) and 2D 
drug assay (Fig.4.B-C), the complex 143B tumouroids underwent a significantly (p<0.0001) 
higher change in metabolic activity than basic tumouroids in response to doxorubicin (Fig.4.E.). 
A similar observation was made for MG63 tumouroids as complex ECM composition resulted 
in a trending but not significant increase of metabolic activity after drug-treatment (Fig.4.G.). 
Interestingly, the low-metastatic MG63 cells showed a trend, although not significant, 
resilience to doxorubicin-induced cell death when in the complex ECM (Fig.4.F.).   
4. Discussion
 Herein, a geometrically compartmentalised 3D model of osteosarcoma was developed, which 
was composed of a core ACM and a surrounding acellular ECM compartment. Key material 
aspects were incorporated into the 3D model in the form of solid bone granules and bone-
marrow matrix proteins to enable the investigation of cancer cell invasion patterns and drug 
responses in a biologically relevant environment.  
The application of 3D models in cancer research has grown in the last two decades [21, 22], 
with promising approaches being borrowed from tissue engineering [23-26] to provide in vitro 
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models with both biological relevance and high-throughput potential for drug-screening; e.g. 
3D tumour spheroids [27] and the hanging-drop method [28]. Several of these approaches have 
cast new light on basic cancer biology and re-emphasised how the tumour microenvironment 
dictates cancer fate [29, 30]. As the field progresses for most epithelial cancers, rare cancers 
such as osteosarcoma have been marginalised in terms of novel drug discovery and preclinical 
model development.  Indeed, although in vitro osteosarcoma models have been reported and 
reviewed for their relevance to the disease in vivo [31], most models are either scaffold-free, to 
provide flexibility, or are scaffold-based to provide the 3D structure - none combine both.  The 
geometrically compartmentalised tumouroids described herein combine flexibility and 3D 
structure. This provides the opportunity to study how the matrix component of the stroma, 
which was developed to reproduce the physical niche in bone, changes cancer invasion and 
drug response.
Collagen type I is the most prevalent ECM protein in bone and its increased expression and 
linearized fibrils have been associated with cancer progression [32]. It has been shown in vitro 
that invasive cancer cells have a higher affinity for matrices expressing the collagen type I 
peptide motif GFOGER (where O=hydroxyproline) and laminin-111 motif IKVAV [33], the 
components of our basic tumouroid cultures. Collagen-based hydrogels have a restricted 
stiffness range which can limit applications for preclinical osteosarcoma research [34, 35]. 
Through the use of the compression technique collagen hydrogels were generated  with an 
average break force of 0.216 Newtons [36] and a mean tensile break strength of 0.6 ± 0.11 MPa 
with modulus of 1.5 ± 0.36 MPa [37], along with an ~48-fold increase in protein density to 
120mg/ml [38]. Although this may not approximate the physiological properties of bone, the 
plastic compression method has been shown to promote cell proliferation and migration, which 
is expected of stiff matrices [39]. Bone with osteosarcoma, like its healthy counterpart, 
undergoes constant remodelling and dynamic homeostasis during which transformed 
osteoblasts/MSCs deposit pre-mineralised osteoid composed of 95% collagen type I. As such, 
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it was considered an appropriate baseline substrate for priming physiological osteosarcoma 
behaviour. 
A specific organisation of cells in 3D and distinct migration patterns were recorded in 
tumouroids. High-metastatic 143B tumouroids with basic matrix composition (collagen I + 
laminin) formed cell clusters in the ACM by day 2 and then invaded the surrounding acellular 
ECM by day 5 of culture, predominantly as cell sheets (Fig. 2.C.). The equivalent low-
metastatic MG63 tumouroids exhibited similar behaviour. Previous work on collective sheet-
like migration described this as a modular control system; boundary cells are converted into 
pioneers while the rest of the cells trace and follow the pattern of pioneers through cell-cell 
coordination in a growth-factor independent manner [40]. 
Both 143B and MG63 tumouroids exhibited another collective cell migration pattern in the 
form of 3D invasive bodies with a spheroid-like morphology. These irregular spheroids grew 
either attached to the ACM or detached and migrated into the surrounding acellular ECM 
(Fig.2.D.). High-metastatic 143B tumouroids produced significantly larger spheroids compared 
to the low-metastatic MG63 cultures (Fig.2.G.). This was apportioned to the 3-fold higher 
proliferation rate (Fig.2.H.) and the high metastatic potential of 143B cells [18]. The generation 
of spheroids may also be key when evaluating patient-derived osteosarcoma tumouroids since 
a similar pattern of cell migration in colorectal cancer reportedly acted as an independent 
indicator of distant metastases and poor survival [41]. It is important to highlight that although 
other hallmarks of cancer are missing from this model, the introduction of a biomimetic matrix 
in 3D in vitro was sufficient to induce phenotypes that are linked to in vivo.
Within the complex osteosarcoma model described herein, the material properties of the 
biomimetic ‘bone’ compartment containing collagen, cancer cells and NuOss® bone granules, 
are different to the biomimetic ‘bone marrow’ component that is the collagen-laminin-
fibronectin surround. Indeed, the addition of NuOss® bone granules most likely made the ACM 
stiffer. Although outside of the remit of this study, it is interesting to note that invasion of both 
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the 143B and MG63 cells in 3D, at least in terms of sheet invasion, was significantly greater 
when NuOss® granules were introduced to the ACM (Supp.Fig.3.A-E.). The vast majority of 
studies have described the phenomenon of durotaxis, where cells move to the stiffest part of 3D 
gels [42]. In stark contrast to this, the current study reveals that osteosarcoma cell invasion is 
significantly enhanced (Fig.3.C-E.) where a reverse stiffness gradient exists, in that cells 
embedded in a stiff ‘bone-like’ matrix, invade faster into a ‘softer’ surrounding matrix. This 
likely confirms that the observations made in the current study are indeed invasion, as opposed 
to cell migration, and that invasive pathways are playing a significant role in the morphology 
of invasion (Fig.3.B&3.G.), as well as the rate (Fig.3.C-E.).  
The plasticity of osteosarcoma cells in response to changes in their surrounding matrix was 
recorded both morphologically, in terms of the invasion profile, and molecularly via qPCR. 
Matrix supplementation with NuOss® bone granules led to increased invasive bodies in high-
metastatic 143B tumouroids (Fig.3.D.) and appeared to hinder their migration into the 
surrounding ECM (Fig.3.E.). This was also reflected by low MMP-9 expression (Fig.3.J.). 
Although osteosarcoma in vivo has been associated with high levels of MMP [43-46], cancer 
growth and invasion within this 3D model could be portrayed by a switch to protease-
independent collective cell migration [47]. Low MMP-9 levels could also have been the result 
of high PTEN expression in complex 143B tumouroids (Fig.3.J.), since PTEN expression 
hinders MMP-9 promoter activity via TNFα [48]. In the context of osteosarcoma, PTEN inhibits 
tumour-induced osteoclast differentiation to counteract bone resorption [49]. As such, PTEN 
upregulation in complex 143B tumouroids containing NuOss® bone granules would be an 
expected result of the elevated levels of MCP-1 (Fig.3.J.). MCP-1 is an early-stress response 
signal [50] which in osteosarcoma triggers osteoclastogenesis from monocytes and attracts 
osteoclasts to the cancer site in order to resorb the surrounding bone [51]. This is in agreement 
with previous reports that 143B cells can produce osteolytic tumours in vivo [52] due to the 
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inherent malignancy profile of the immortalised cell line [51]. The addition of NuOss® caused 
143B tumouroids to upregulate MCT-4 (Fig.3.J.), suggesting that the cancer cells shifted 
towards a glycolytic metabolism which is linked to poor cancer-patient survival [53]. As gate-
keeper of lactate efflux, MCT-4 upregulation could also reflect the in vivo phenomenon of 
transformed MSCs promoting osteosarcoma migration via lactate [54]. This is however an 
observation based on the expression of a single gene of the glycolytic switch and more extensive 
molecular analysis would be required to fully elucidate matrix induced metabolic 
reprogramming. It should be noted that on the whole a  divergent gene expression profile was 
observed when comparing MG63 to 143B cells, which has been documented before [55], and 
is likely to reflect the differences in osteosarcoma characteristics. Indeed, as we specifically 
chose genes linked to metastasis, this further confirms that the complex tumouroid is likely to 
be facilitating the cells natural capacity for metastasis.  
The 3D tumouroids described herein were created to interrogate the effects of a biomimetic 
matrix on osteosarcoma behaviour. A limitation of these models is the lack other key elements 
of the tumour microenvironment such as neovascularisation and interaction with other cell 
types. Nevertheless, given the diversity between pioneer cancer cells and follower cells within 
a metastasising tumour in vivo, obtaining analogous morphological and molecular diversity 
within tumouroids illustrates an improved biological relevance. 
To test the capacity of tumouroids as a drug-screening platform we exposed complex and basic 
high-metastatic 143B tumouroids to doxorubicin after an initial 7 day culture-period. It was 
hypothesised that osteosarcoma cells cultured in the complex 3D matrix would infer a distinct 
drug-response compared to cells within a basic matrix. To experimentally test this hypothesis, 
day 7 tumouroids were exposed to 0.1-10 µM doxorubicin hydrochloride for 24h. This 
corresponds to 50-5000 ng/ml doxorubicin, which includes the range of plasma Cmax 
(39.8 ± 15.3 to 630.4 ± 22.1 ng/ml) achieved in individuals with normal body surface area 
(BSA) after a 24h infusion [56]. 
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Analysis of the doxorubicin treated tumouroids revealed 143B cells grown in the complex 
matrix composition underwent a greater rate of change in metabolic activity than basic 
tumouroids in response to doxorubicin (Fig.4.E.) whereas MG63 complex tumouroids only 
trended to an increased rate of metabolic change at 1 μM (Fig.4.G.). Furthermore, the complex 
ECM composition conferred a trend for resistance to drug-induced death in both cell lines 
compared to the basic ECM counterparts (Fig.4.D. & 4.F.). At the highest drug dose, 143B 
complex tumouroids had a greater rate in cell death, which may indicate the requirement for 
higher drug doses or more efficient doxorubicin-like drugs clinically. 143B cells have already 
been shown to generate drug-resistant tumours in vivo [57, 58], confirming that complex 3D 
tumouroids are capable of reproducing aspects of cancer cell behaviour in vitro. Qualitative 
observations of live-dead stained tumouroids with basic and complex ECM composition 
indicated that the majority of cell death existed in the periphery of the ACM (Fig.4.H.) and 
invasive bodies (Fig.4.I.). Following the paradigm of a protective cancer core and limited drug 
penetrance in vivo, this observation is not surprising. The cells at the periphery are exposed to 
the drug for longer time periods hence are more susceptible to cell death. 
Conclusions
The potential mechanisms through which osteosarcoma achieves chemoresistance have been 
reviewed extensively [59], concluding that both the intrinsic cellular profile and the 
extracellular environment impact cancer cell behaviour. To our knowledge, the complex 
osteosarcoma tumouroids described herein are the first geometrically modular 3D cultures to 
incorporate matrix components of the osteosarcoma niche, and capture the adaptive nature of 
tumour cells in response to changes in their surroundings and drug treatment. It is envisaged 
that this body of work will engage the field and generate the impetus for further development 
of biomimetic osteosarcoma models.
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Statement of significance
This study describes the generation of 3D osteosarcoma models termed “tumouroids”, 
which are geometrically compartmentalised to reproduce the bone cancer mass and 
its environment. Utilising this novel model, specific parameters of osteosarcoma 
growth and invasion were investigated. Osteosarcoma cell lines proliferate at a slower 
rate, exhibit malignant metabolic reprogramming, and respond to drug intervention at 
lower concentrations of Doxorubicin Hydrochloride in matrix-complex compared to 
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basic tumouroids.  As such, this study provides evidence that the tumour 
microenvironment impacts osteosarcoma in many ways. The osteosarcoma tumouroid 
described herein may form the basis of a personalised-medicine strategy, which will 
allow the testing of drug effectiveness similar to that used for antibiotic selection for 
pathogenic bacteria. 
  
  
  
  
  
